Published in Hepatology on November 01, 1992
Cloning and sequence analysis of the rat augmenter of liver regeneration (ALR) gene: expression of biologically active recombinant ALR and demonstration of tissue distribution. Proc Natl Acad Sci U S A (1994) 2.35
A fresh look at augmenter of liver regeneration in rats. Hepatology (1999) 1.32
The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions. Hepatology (1997) 1.04
Insights on augmenter of liver regeneration cloning and function. World J Gastroenterol (2006) 1.01
Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors. J Hepatol (2002) 0.88
Hepatic stimulator substance activity in animal model of fulminant hepatic failure and encephalopathy. Dig Dis Sci (2002) 0.75
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Growth factors and cancer. Cancer Res (1986) 3.48
Liver regeneration: molecular mechanisms of growth control. FASEB J (1990) 3.34
Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci U S A (1988) 2.62
Growth-stimulating factor in regenerating canine liver. Lancet (1979) 2.61
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
The Eck fistula in animals and humans. Curr Probl Surg (1983) 2.35
Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci U S A (1989) 2.35
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Hormonal stimulation of DNA synthesis in primary cultures of adult rat hepatocytes. Proc Natl Acad Sci U S A (1976) 2.23
Control of hepatocyte replication by two serum factors. Cancer Res (1984) 2.20
Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res (1986) 1.97
Induction of deoxyribonucleic acid synthesis in the liver of the intact animal. J Biol Chem (1972) 1.85
Transforming growth factors. Cancer Surv (1985) 1.52
Extraction and partial purification of a hepatic stimulatory substance in rats, mice, and dogs. Cancer Res (1987) 1.43
Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. Hepatology (1991) 1.30
Altered responses of regenerating hepatocytes to norepinephrine and transforming growth factor type beta. J Cell Physiol (1989) 1.05
Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. Transplantation (1991) 1.01
Transforming growth factor receptors in liver regeneration following partial hepatectomy in the rat. Cancer Res (1990) 0.95
Evolution of liver transplantation. Hepatology (1982) 19.54
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
A gene (RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3). Nat Genet (1996) 3.31
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Changes in blood coagulation. Arch Surg (1966) 3.22
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Changes in surface morphology of Chinese hamster ovary cells during the cell cycle. J Cell Biol (1973) 3.14
Fungal infections in liver transplant recipients. Transplantation (1985) 3.07
De novo malignant tumors in organ transplant recipients. Transplant Proc (1971) 3.03
Experience with 150 liver resections. Ann Surg (1983) 3.01
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00
Death after transplantation; an analysis of sixty cases. Am J Med (1967) 2.99
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev (1971) 2.94
Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92
Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Liver transplantation in adults. Hepatology (1982) 2.89
Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80
Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis (1988) 2.76
Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts. Ann Intern Med (1968) 2.72
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
Growth-stimulating factor in regenerating canine liver. Lancet (1979) 2.61
Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J (1999) 2.61
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Portal vein grafts in hepatic transplantation. Surg Gynecol Obstet (1985) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
Studies of blood flow and ultrastructural changes in rejecting and nonrejecting canine orthotopic liver homografts. Surgery (1968) 2.58